StereoTactic Ablative RadioTherapy of Cardiac Arrhythmias (START-CA)

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Apr 11, 2021

Keywords

ClinConnect Summary

The START-CA trial is a study looking at a new way to treat patients with a heart condition called cardiac arrhythmia, which affects how the heart beats. This trial is testing a special type of treatment called stereotactic ablative radiotherapy (SBRT). This is a targeted radiation therapy that aims to improve heart function in patients who have not responded well to standard treatments, like medication or previous procedures to correct their heart rhythm. The main goal of the study is to observe the heart health of participants after they receive this treatment.

To be eligible for this trial, patients need to have a specific type of arrhythmia that hasn't improved with usual treatments. They also need to be in good enough health to undergo SBRT, as determined by their doctor. The study is currently recruiting participants aged 65 to 74, and it is open to all genders. If someone joins the trial, they can expect to be closely monitored for their heart health after receiving the treatment. It's important to note that patients who have already had high doses of radiation in the same area or have other health issues that prevent them from receiving radiation may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with heart rate and rhythm condition (arrhythmia) who have failed standard of care treatment with medication OR at least one prior invasive catheter ablation procedure.
• • Patients deemed medically fit to receive stereotactic ablative radiotherapy as determined by their Radiation Oncologist.
• Exclusion Criteria:
• • Patients who have previously received high dose radiotherapy to the target area and cannot safely receive further treatment OR are unable to receive radiotherapy due to other contraindications.